QL-SM-10

Overview

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist. It is the most extensively clinically validated GLP-1 compound in existence, with over a decade of published human data spanning metabolic, cardiovascular, and emerging neurological research domains. Structurally, semaglutide is a modified GLP-1 analogue with 94% sequence homology to native GLP-1, modified at position 8 (Aib substitution) to resist DPP-4 degradation and acylated with a C18 fatty acid chain enabling albumin binding for an extended half-life of approximately 7 days.

Primary Research Areas

• GLP-1 receptor agonism -- binding kinetics, downstream cAMP signaling, and receptor internalization/recycling studies
• Appetite signaling research -- hypothalamic GLP-1R activation, food intake regulation, and central satiety pathway mapping
• Insulin secretion biology -- glucose-dependent insulinotropic activity in pancreatic beta-cell models and islet preservation studies
• Cardiovascular outcome studies -- MACE endpoint research, vascular biology, and endothelial function (SUSTAIN-6, SELECT trial data)
• Neurological GLP-1 pathways -- emerging CNS GLP-1R research in neuroinflammation, Alzheimer's disease, and Parkinson's disease models
• Gastric motility -- delayed gastric emptying mechanisms and gut-brain axis signaling